The influence of urinary pH on flecainide excretion and its serum pharmacokinetics.
The effect of urinary pH on flecainide excretion has been evaluated in six healthy subjects after a single oral dose of 300 mg flecainide administered as the acetate salt. The cumulative urinary excretion of unchanged flecainide under acidic conditions (134.0 +/- 16.1 mg; mean +/- s.e. mean) was significantly higher than under alkaline conditions (22.3 +/- 7.6 mg; mean +/- s.e. mean) (P less than 0.01). Under alkaline conditions, tmax (time to reach peak concentration) was reduced (P less than 0.01), while elimination half-life, AUC(0-32) and AUC(0-infinity) were increased (P less than 0.01).
D000328:Adult; D000643:Ammonium Chloride / Q000494:pharmacology; D001639:Bicarbonates / Q000494:pharmacology; D005260:Female; D005424:Flecainide; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D008297:Male; D010880:Piperidines / Q000097:blood / Q000378:metabolism* / Q000652:urine; D017693:Sodium Bicarbonate
D001639:Bicarbonates; D010880:Piperidines; D000643:Ammonium Chloride; D017693:Sodium Bicarbonate; D005424:Flecainide